Drug intelligence / Profile preview

amlodipine + botulinum toxin

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Intramuscular

Overview

A combination therapy being investigated where amlodipine (a calcium channel blocker) is used to potentially augment the effects of botulinum toxin injections in the treatment of focal dystonia. Botulinum toxin works by blocking nerve signals that cause muscles to contract, resulting in muscle relaxation. Amlodipine belongs to a class of medications called calcium channel blockers that relax blood vessels. The combination is being studied to determine if amlodipine can enhance the therapeutic effects of botulinum toxin in patients with focal dystonia.

Targets

VAMP (SNARE Protein Complex)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on amlodipine + botulinum toxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + botulinum toxin.

Explore the full profile